Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $765.00 at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price raised by Royal Bank Of Canada from $745.00 to $765.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective would indicate a potential downside of 2.41% from the company’s previous close.

A number of other brokerages have also commented on REGN. UBS Group upped their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Scotiabank raised their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Finally, Canaccord Genuity Group boosted their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $796.52.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $2.26 on Monday, reaching $783.93. The company had a trading volume of 163,202 shares, compared to its average volume of 822,240. The stock has a market cap of $82.88 billion, a P/E ratio of 18.87, a P/E/G ratio of 2.10 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company’s fifty day moving average is $771.59 and its 200 day moving average is $682.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company posted $12.07 earnings per share. The business’s revenue was up 2.5% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Insigneo Advisory Services LLC boosted its holdings in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 13 shares during the last quarter. Guardian Wealth Advisors LLC NC lifted its position in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the last quarter. MCF Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 15 shares during the period. Finally, Rexford Capital Inc. raised its stake in Regeneron Pharmaceuticals by 5.5% during the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 15 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.